The in vivo and in vitro results performed on a CRC model demonstrated that the combined treatment between cetuximab and MEKi has synergic anti-proliferative and pro-apoptotic properties, combined with MAPK and PI3K/AKT/mTOR inhibition [165]. This evidence concerns the gene PIK3CA and colorectal carcinoma.